Anima vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI care enablement platform resolving 85% of patient inquiries within one day; $12M Series A from Molten Ventures helping clinics manage NHS and value-based care patient caseloads.
About
Anima is a care enablement platform that uses AI to help clinical teams manage patient caseloads more efficiently — enabling practices, clinics, and healthcare systems to handle more patient inquiries with the same clinical staff by triaging, routing, and pre-processing patient messages, symptoms, and administrative requests before they reach clinicians. Founded as a Y Combinator W21 graduate, Anima raised $14.5 million total including a $12 million Series A in early 2024 led by Molten Ventures with Hummingbird, achieving a benchmark of resolving 85% of patient inquiries within one day.\n\nAnima's platform integrates with existing EHR systems and clinical workflows — when patients submit messages or requests, Anima's AI layer categorizes the urgency, extracts relevant clinical context from the patient record, and routes to the appropriate care team member with pre-populated response templates and suggested actions. Administrative inquiries (prescription refills, appointment requests, test result questions) are handled with AI-assisted responses that clinicians can review and approve rapidly rather than composing from scratch. This reduces the cognitive load of clinical inbox management that contributes to physician burnout.\n\nIn 2025, Anima competes in the clinical workflow automation and care management platform market with Klara (patient communication), Luma Health (care orchestration), Healthie, and AI-powered EHR tools from Epic and athenahealth for clinical team productivity and patient communication. The UK National Health Service (NHS) has been a key market for Anima, given the NHS's acute GP workload crisis and the need for digital tools that help manage the high volume of patient contacts with limited clinical capacity. The 2025 strategy focuses on expanding within NHS primary care networks, growing in US value-based care organizations where managing population health efficiently is financially incentivized, and deepening AI capabilities for clinical decision support.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.